Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05239143 | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 180 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04762953 | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis(STOPGAP) | active not recruiting | Phase 2 | 40 | University of California, IrvineOTHER | 1 | Feb 3, 2026 |
| clinicaltrials |
| NCT03257163 | Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer | active not recruiting | Phase 2 | 40 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT00582647 | Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | active not recruiting | — | 6,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05156866 | First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer | active not recruiting | Phase 1 | 163 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Jan 13, 2026 | clinicaltrials |
| NCT07312500 | Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer | active not recruiting | — | 3,000 | Fudan UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07257575 | A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma | active not recruiting | Phase 2 | 138 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06328738 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | active not recruiting | Phase 1 | 275 | Enliven TherapeuticsINDUSTRY | 7 | Nov 19, 2025 | clinicaltrials |
| NCT05205330 | Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | active not recruiting | Phase 1 / Phase 2 | 107 | Rottapharm BiotechINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04931654 | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | active not recruiting | Phase 1 / Phase 2 | 136 | AstraZenecaINDUSTRY | 10 | Oct 9, 2025 | clinicaltrials |
| NCT05177068 | Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer | active not recruiting | Phase 2 | 42 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05980481 | A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer | active not recruiting | Phase 2 / Phase 3 | 201 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06902337 | Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany(MaGen) | active not recruiting | — | 75,000 | Medizinische Hochschule Brandenburg Theodor FontaneOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05632939 | ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. | active not recruiting | Phase 1 / Phase 2 | 62 | AskGene Pharma, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07147452 | Sentinel Lymph Node Detection in Gastric Cancer Using a Dual Tracer (Superparamagnetic Iron Oxide and Methylene Blue): A Prospective Study With Histological and OSNA Validation(SLN_GC_SPIO) | active not recruiting | — | 44 | Hospital del SAS de JerezOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT05029869 | Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description | active not recruiting | — | 100 | University Medical Center Ho Chi Minh City (UMC)OTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07113340 | Carina™ Surgical Platform for Minimal Radical Gastrectomy | active not recruiting | N/A | 20 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05002127 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | active not recruiting | Phase 2 / Phase 3 | 127 | ALX Oncology Inc.INDUSTRY | 12 | Aug 7, 2025 | clinicaltrials |
| NCT07104877 | A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors | active not recruiting | N/A | 25 | Fujian Cancer HospitalOTHER_GOV | 1 | Aug 5, 2025 | clinicaltrials |
| NCT03421288 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness(DANTE) | active not recruiting | Phase 2 | 677 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Jul 25, 2025 | clinicaltrials |
| NCT07080879 | The Advantages and Disadvantages of Linear Anastomat and Tubular Anastomat in Radical Gastrectomy of Distal Gastric Cancer | active not recruiting | N/A | 250 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03348150 | Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.(PERISCOPEII) | active not recruiting | Phase 3 | 102 | The Netherlands Cancer InstituteOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06427252 | The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06939439 | Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer | active not recruiting | Phase 3 | 416 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT04384757 | Comparison of Open and Laparoscopic Distal Gastrectomy for T4a Gastric Cancer | active not recruiting | N/A | 240 | University Medical Center Ho Chi Minh City (UMC)OTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial(PLATFORM) | active not recruiting | Phase 2 | 494 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT03448835 | Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)(PANDA) | active not recruiting | Phase 2 | 20 | The Netherlands Cancer InstituteOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04581473 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | active not recruiting | Phase 1 / Phase 2 | 192 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06997302 | A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal Malignancies | active not recruiting | N/A | 150 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT06940778 | LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORS(BLENTI) | active not recruiting | — | 273 | Hospital do CoracaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06938139 | Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy | active not recruiting | — | 90,000 | Fujian Medical UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04166721 | WaKING: Wnt and checKpoint INhibition in Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06877910 | Deciphering the Molecular Traits of Non-canonical Responders to Advance Personalized Therapy in Gastric Cancer | active not recruiting | — | 220 | Regina Elena Cancer InstituteOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT01924819 | Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma(TOPGEAR) | active not recruiting | Phase 2 / Phase 3 | 574 | Australasian Gastro-Intestinal Trials GroupNETWORK | 10 | Mar 4, 2025 | clinicaltrials |
| NCT06856382 | The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer | active not recruiting | — | 20 | Dong PengOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05165264 | A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer(INGA) | active not recruiting | — | 600 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06854146 | The Effect of Environmental Factors on Gastric Cancer Based on Macrogenome | active not recruiting | — | 200 | Dong PengOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT05586061 | First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer(RCTS) | active not recruiting | Phase 2 | 55 | Qilu Hospital of Shandong UniversityOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06790238 | POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)(POWER 4 + 3) | active not recruiting | — | 350 | Grupo Español de Rehabilitación MultimodalOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04404595 | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | active not recruiting | Phase 1 / Phase 2 | 110 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Jan 8, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04593615 | Indocyanine Green Tracer Using in Laparoscopic Radical Gastrectomy for Locally Advanced Gastric Cancer(CLASS-11) | active not recruiting | N/A | 1,070 | Fujian Medical UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT02112214 | Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population(HELPER) | active not recruiting | Phase 3 | 5,224 | National Cancer Center, KoreaOTHER_GOV | 1 | Dec 27, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Feb 9, 2026source: clinicaltrials